Literature DB >> 27659365

Radiopathological features predictive of involved margins in ductal carcinoma in situ.

D M Layfield1, H See1, M Stahnke2, L Hayward1, R I Cutress1,2,3, R S Oeppen2,3.   

Abstract

INTRODUCTION Ductal carcinoma in situ (DCIS) usually manifests as microcalcification on mammography but may be uncalcified. Consequently, a quarter of patients undergoing excision of a presumed pure DCIS require further surgery to re-excise margins. Patients at highest risk of margin involvement may benefit from additional preoperative assessment. METHODS A retrospective review was carried out of patients treated for screen detected, biopsy proven DCIS in a single centre over a ten-year period (1999-2009). Logistic regression analysis identified factors predictive of need for further surgery to clear margins. RESULTS Overall, 248 patients underwent surgery for DCIS (low/intermediate grade: 82, high grade: 155) and 49 (19.8%) required further surgery. High grade disease was associated with greater mammographic extent (mean: 32mm [range: 5-120mm] vs 25mm [range: 2-100mm]), p=0.009) and higher incidence of mastectomy (38% vs 24%, p=0.034). Factors predictive of involvement of surgical margins necessitating further surgery included negative oestrogen receptor status (OR: 5.2, 95% CI: 2.1-12.8, p<0.001) and mammographic extent (odds ratio [OR]: 1.6, 95% confidence interval [CI]: 1.2-2.1, p=0.004). Once size exceeded 30mm, more than 50% of patients required secondary breast surgery for margins. CONCLUSIONS Reoperation rates for DCIS increase with preoperative size on mammography and negative oestrogen receptor status on core biopsy. Patients with these risk features should be counselled accordingly and consideration should be given to the role of additional preoperative imaging.

Entities:  

Keywords:  Breast; Ductal carcinoma in situ; Margin; Revision surgery; Screening

Mesh:

Year:  2016        PMID: 27659365      PMCID: PMC5392827          DOI: 10.1308/rcsann.2016.0299

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  27 in total

1.  Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.

Authors:  Meagan E Brennan; Robin M Turner; Stefano Ciatto; M Luke Marinovich; James R French; Petra Macaskill; Nehmat Houssami
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

2.  Surgical guidelines for the management of breast cancer.

Authors: 
Journal:  Eur J Surg Oncol       Date:  2009-03-18       Impact factor: 4.424

3.  Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.

Authors:  Carlos Vargas; Larry Kestin; Nel Go; Daniel Krauss; Peter Chen; Neal Goldstein; Alvaro Martinez; Frank A Vicini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-11       Impact factor: 7.038

4.  The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy.

Authors:  Mariko Goto; Sachiko Yuen; Kentaro Akazawa; Kaori Nishida; Eiichi Konishi; Mariko Kajihara; Nobuhiko Shinkura; Kei Yamada
Journal:  Eur Radiol       Date:  2011-12-30       Impact factor: 5.315

5.  Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE).

Authors:  L W Turnbull; S R Brown; C Olivier; I Harvey; J Brown; P Drew; A Hanby; A Manca; V Napp; M Sculpher; L G Walker; S Walker
Journal:  Health Technol Assess       Date:  2010-01       Impact factor: 4.014

6.  Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only.

Authors:  Mary F Dillon; Enda W McDermott; Cecily M Quinn; Ann O'Doherty; Niall O'Higgins; Arnold D K Hill
Journal:  J Surg Oncol       Date:  2006-06-01       Impact factor: 3.454

7.  Magnetic resonance evaluation of the presence of an extensive intraductal component in breast cancer.

Authors:  O Ikeda; R Nishimura; H Miyayama; T Yasunaga; Y Ozaki; A Tsuji; Y Yamashita
Journal:  Acta Radiol       Date:  2004-11       Impact factor: 1.990

8.  Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

Authors:  Gaiane M Rauch; Henry M Kuerer; Marion E Scoggins; Patricia S Fox; Ana P Benveniste; Young Mi Park; Sara A Lari; Brian P Hobbs; Beatriz E Adrada; Savitri Krishnamurthy; Wei T Yang
Journal:  Breast Cancer Res Treat       Date:  2013-06-18       Impact factor: 4.872

9.  Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass.

Authors:  Paul C Stomper; Joseph Geradts; Stephen B Edge; Ellis G Levine
Journal:  AJR Am J Roentgenol       Date:  2003-12       Impact factor: 3.959

10.  Magnetic resonance imaging in size assessment of invasive breast carcinoma with an extensive intraductal component.

Authors:  Arjan P Schouten van der Velden; Carla Boetes; Peter Bult; Theo Wobbes
Journal:  BMC Med Imaging       Date:  2009-04-07       Impact factor: 1.930

View more
  3 in total

1.  Radiological Underestimation of Tumor Size as a Relevant Risk Factor for Positive Margin Rate in Breast-Conserving Therapy of Pure Ductal Carcinoma In Situ (DCIS).

Authors:  Gesche Schultek; Bernd Gerber; Toralf Reimer; Johannes Stubert; Steffi Hartmann; Annett Martin; Angrit Stachs
Journal:  Cancers (Basel)       Date:  2022-05-11       Impact factor: 6.575

2.  Predictors of Reexcision following Breast-Conserving Surgery for Ductal Carcinoma In Situ.

Authors:  Leslie R Lamb; Sarah Mercaldo; Tawakalitu O Oseni; Manisha Bahl
Journal:  Ann Surg Oncol       Date:  2020-09-10       Impact factor: 5.344

3.  Indications and methods of intraoperative specimen radiography in breast-conserving surgery.

Authors:  Ji Young Kim; Yong Sik Jung; Se Hwan Han; Ji Hyun Sung; Min Hee Hur
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.